As we enter the second half of the year, pharma companies are still frantically engaged in the search for a COVID-19 vaccine. There are many companies in the mix, but it is not a level playing field, as big players are pitted against smaller names. At the onset of the pandemic, Novavax (NVAX) stood squarely in the latter camp. Facing pharma giants such as Pfizer, AstraZeneca and J&J, the small-cap biotech was at a disadvantage from the start. However, the vaccine specialist has become a force to be reckoned with. The incredible share gains (almost 1,855% year-to-date) which have pushed the market cap up to $4.6 billion, and various grants that have significantly bolstered the balance sheet, have positioned it as a real contender. However, it shouldn’t be forgotten that Novavax is still a ways away from presenting a solution to the public. Yet, according to H.C. Wainwright analyst Vernon Bernardino,...
I don't have to tell you how well Nvidia (NASDAQ:NVDA) stock has performed these past few months. The novel coronavirus wound up being a tailwind, not a headwind, for the chip giant. Shares more than doubled off their March sell-off lows. But that's just the start.Source: Hairem / Shutterstock.com Why? Valuation may be rich. But it's more than justified. With so many growth catalysts in motion and "megatrends" on its side, this powerhouse remains "best in class." As the pandemic continues to linger, hard-hit stocks like airlines, cruise lines, and retail could continue to be challenged.Strong growth stories like Nvidia? It's going to be different. Sure, there may be some hiccups in the near-term. But don't expect this company's growth trajectory to change course anytime soon. Demand in the company's existing end markets (cloud computing, data center, video games) continues to grow. To top it all off, their exposure to emerging...
American satellite radio leader Sirius XM (NASDAQ:SIRI) had put together a pretty solid five years of growth. Up until the novel coronavirus pandemic hit, that is. Starting in February, SIRI stock went off a cliff, with shares losing 40% of their value in just four weeks. Since hitting a four-year low of $4.44 in late March, SIRI has begun to claw its way back -- but it's been a rocky road. Now trading at $5.87, it remains well under its 2020 high close of $7.34, which makes the stock an interesting proposition for those willing to take on some risk.Source: Shutterstock This C-rated stock has real potential to at least regain the levels it traded at in February. With that alone representing 25% upside, it's worth looking at what the future looks like for SiriusXM. But again, before we go further, keep in mind that the prospects here are more risky...
